Form 4: Bio-Rad Laboratories Director Allison Schwartz Reports Acquisition of Restricted Stock Units

Director Allison Schwartz reports acquisition of 369 restricted stock units in Bio-Rad Laboratories, vesting over four years.

Summary

• On September 6, 2024, Allison Schwartz, a director of Bio-Rad Laboratories, reported the acquisition of 369 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Bio-Rad Class A common stock each.
• The RSUs vest over a period of four years, with 25% vesting annually on the anniversary date of the grant.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of RSUs by a director is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The RSUs vest over four years, indicating a long-term incentive for the director.

Industry Context

Acquisition of stock options and restricted stock units are common forms of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation for board members varies widely based on company size, industry, and performance.
• Companies like Danaher and Thermo Fisher Scientific, which are Bio-Rad's competitors, also use stock options and RSUs as part of their director compensation packages.
• The vesting schedule of four years is a fairly standard practice to ensure long-term commitment.

Stakeholder Impact

• The acquisition of RSUs by a director aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates